Uterine Cancer Diagnostic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025

Description

Persistence Market Research has recently released a comprehensive report on the global Uterine Cancer Diagnostic Testing Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

Uterine Cancer Diagnostic Testing Market Size (2025E): US$ 3,547.10 Mn
Projected Market Value (2032F): US$ 6,738.90 Mn
Global Market Growth Rate (CAGR 2025 to 2032): 9.60%

Uterine Cancer Diagnostic Testing Market - Report Scope:

The global uterine cancer diagnostic testing market comprises diagnostic solutions such as ultrasound scanning, biopsy procedures, and blood tests aimed at detecting uterine cancer, which includes endometrial carcinoma and uterine sarcoma. The market growth is driven by the increasing prevalence of uterine cancer, advancements in diagnostic technologies, and the rising geriatric population. Improved healthcare infrastructure, awareness programs, and government initiatives also support market expansion.

Market Drivers:

Several factors are propelling the growth of the global uterine cancer diagnostic testing market. The rising prevalence of uterine cancer, particularly among post-menopausal and obese women, underscores the demand for early detection methods. Advances in diagnostic techniques, such as transvaginal ultrasound scanning and CA125 tumor marker blood tests, have improved accuracy and reliability, fueling market adoption. Increasing healthcare expenditure, especially in emerging economies, supports the development and accessibility of diagnostic solutions. Furthermore, government initiatives promoting women's health and cancer screenings, combined with rising awareness about early diagnosis, contribute significantly to market growth.

Market Restraints:

Despite the promising growth trajectory, the uterine cancer diagnostic testing market faces several challenges. High costs associated with advanced diagnostic procedures and limited healthcare infrastructure in certain regions can hinder market penetration. Awareness about uterine cancer diagnosis remains low in developing countries, impacting timely detection and treatment. The complexity and invasiveness of certain diagnostic procedures, such as dilation and curettage, may deter patients, particularly in regions with cultural and social barriers to medical intervention.

Market Opportunities:

The uterine cancer diagnostic testing market offers significant growth opportunities driven by technological advancements and expanding healthcare access. Development of minimally invasive diagnostic tools enhances patient compliance and broadens market adoption. Emerging economies present untapped potential due to increasing investments in healthcare infrastructure and government-backed initiatives for cancer screenings. Partnerships between diagnostic solution providers and healthcare organizations can accelerate innovation and expand service delivery. Additionally, the growing focus on personalized medicine and precision diagnostics provides new avenues for market expansion.

Key Questions Answered in the Report:

1. What are the primary factors driving the global growth of the uterine cancer diagnostic testing market?

2. Which diagnostic solutions are gaining the highest adoption across different regions?

3. How are advancements in diagnostic technologies shaping the competitive landscape of the uterine cancer diagnostic testing market?

4. Who are the key players in the uterine cancer diagnostic testing market, and what strategies are they employing to maintain their market positions?

5. What are the emerging trends and future outlooks for the global uterine cancer diagnostic testing market?

Competitive Intelligence and Business Strategy:

Leading companies in the global uterine cancer diagnostic testing market, such as Siemens Healthineers, Hologic, and GE Healthcare, are focusing on technological innovations and expanding their product portfolios to gain a competitive edge. These companies are leveraging collaborations with healthcare providers and research institutions to accelerate the development of advanced diagnostic solutions. Investments in AI-based imaging and non-invasive diagnostic technologies further support market growth. Additionally, companies are emphasizing affordability and accessibility to cater to diverse patient demographics, particularly in emerging economies.

Key Companies Profiled:

Abbott
Roche Holdings AG
Siemens AG
Danaher
BioMerieux SA
Others

Uterine Cancer Diagnostic Testing Market Segmentation:

By Cancer Type:

Endometrial Carcinoma
Uterine Sarcoma

By Diagnostic Test Type:

Ultrasound Scanning
Biopsy Procedures
Blood Tests

By End User:

Hospitals
Ambulatory Surgical Centers
Cancer Research Institutes
Specialized Clinics
Diagnostic Laboratories

By Region:

North America
Europe
Latin America
South East Asia & Pacific
Middle East & Africa (MEA)
China
Japan

Product Code: PMRREP17005

1. Executive Summary

1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction

2.1. Market Definition
2.2. Market Taxonomy

3. Uterine Cancer Diagnostic Testing Market View Point

3.1. Macro-Economic Factors
3.2. Market Drivers and Restraints
3.3. Opportunity Analysis
3.4. Global Key trends
3.5. Reimbursement Scenario

4. Global Uterine Cancer Diagnostic Testing Market - Key Inclusions

4.1. Regional Average Pricing Analysis
4.2. Parent Market Assessment
4.3. Epidemiology

5. North America Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

5.1. Introduction
5.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
- 5.2.1. U.S.
- 5.2.2. Canada
5.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
- 5.3.1. U.S.
- 5.3.2. Canada
5.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
- 5.4.1. Uterine Sarcoma
- 5.4.2. Endometrial Carcinomas
5.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
- 5.5.1. Uterine Sarcoma
- 5.5.2. Endometrial Carcinomas
5.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
- 5.6.1. Ultrasound Scanning
  - 5.6.1.1. Abdominal Ultrasound
  - 5.6.1.2. Transvaginal Ultrasound
- 5.6.2. Biopsy
  - 5.6.2.1. Endometrial Biopsy
  - 5.6.2.2. Hysteroscopy
  - 5.6.2.3. Dilation and curettage
- 5.6.3. Blood tests
  - 5.6.3.1. Complete blood Count
  - 5.6.3.2. CA-125 blood test
5.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
- 5.7.1. Ultrasound Scanning
  - 5.7.1.1. Abdominal Ultrasound
  - 5.7.1.2. Transvaginal Ultrasound
- 5.7.2. Biopsy
  - 5.7.2.1. Endometrial Biopsy
  - 5.7.2.2. Hysteroscopy
  - 5.7.2.3. Dilation and curettage
- 5.7.3. Blood tests
  - 5.7.3.1. Complete blood Count
  - 5.7.3.2. CA-125 blood test
5.8. Historical Market Size Analysis 2019 - 2024, By End User
- 5.8.1. Hospitals
- 5.8.2. Ambulatory Surgical Centers
- 5.8.3. Cancer Research Centers
- 5.8.4. Specialized Clinics
- 5.8.5. Diagnostic Laboratories
- 5.8.6. Others
5.9. Market Size Analysis 2025 - 2032, By End User
- 5.9.1. Hospitals
- 5.9.2. Ambulatory Surgical Centers
- 5.9.3. Cancer Research Centers
- 5.9.4. Specialized Clinics
- 5.9.5. Diagnostic Laboratories
- 5.9.6. Others
5.10. Drivers and Restraints: Impact Analysis
5.11. Market Attractiveness Analysis
- 5.11.1. By Cancer Type
- 5.11.2. By Test Type
- 5.11.3. By End user
- 5.11.4. By Country

6. Latin America Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

6.1. Introduction
6.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
- 6.2.1. Brazil
- 6.2.2. Mexico
- 6.2.3. Rest of Latin America
6.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
- 6.3.1. Brazil
- 6.3.2. Mexico
- 6.3.3. Rest of Latin America
6.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
- 6.4.1. Uterine Sarcoma
- 6.4.2. Endometrial Carcinomas
6.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
- 6.5.1. Uterine Sarcoma
- 6.5.2. Endometrial Carcinomas
6.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
- 6.6.1. Ultrasound Scanning
  - 6.6.1.1. Abdominal Ultrasound
  - 6.6.1.2. Transvaginal Ultrasound
- 6.6.2. Biopsy
  - 6.6.2.1. Endometrial Biopsy
  - 6.6.2.2. Hysteroscopy
  - 6.6.2.3. Dilation and curettage
- 6.6.3. Blood tests
  - 6.6.3.1. Complete blood Count
  - 6.6.3.2. CA-125 blood test
6.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
- 6.7.1. Ultrasound Scanning
  - 6.7.1.1. Abdominal Ultrasound
  - 6.7.1.2. Transvaginal Ultrasound
- 6.7.2. Biopsy
  - 6.7.2.1. Endometrial Biopsy
  - 6.7.2.2. Hysteroscopy
  - 6.7.2.3. Dilation and curettage
- 6.7.3. Blood tests
  - 6.7.3.1. Complete blood Count
  - 6.7.3.2. CA-125 blood test
6.8. Historical Market Size Analysis 2019 - 2024, By End User
- 6.8.1. Hospitals
- 6.8.2. Ambulatory Surgical Centers
- 6.8.3. Cancer Research Centers
- 6.8.4. Specialized Clinics
- 6.8.5. Diagnostic Laboratories
- 6.8.6. Others
6.9. Market Size Analysis 2025 - 2032, By End User
- 6.9.1. Hospitals
- 6.9.2. Ambulatory Surgical Centers
- 6.9.3. Cancer Research Centers
- 6.9.4. Specialized Clinics
- 6.9.5. Diagnostic Laboratories
- 6.9.6. Others
6.10. Drivers and Restraints: Impact Analysis
6.11. Market Attractiveness Analysis
- 6.11.1. By Cancer Type
- 6.11.2. By Test Type
- 6.11.3. By End user
- 6.11.4. By Country

7. Europe Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

7.1. Introduction
7.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
- 7.2.1. Germany
- 7.2.2. U.K.
- 7.2.3. France
- 7.2.4. Italy
- 7.2.5. Spain
- 7.2.6. Poland
- 7.2.7. Russia
- 7.2.8. Rest of Europe
7.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
- 7.3.1. Germany
- 7.3.2. U.K.
- 7.3.3. France
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Poland
- 7.3.7. Russia
- 7.3.8. Rest of Europe
7.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
- 7.4.1. Uterine Sarcoma
- 7.4.2. Endometrial Carcinomas
7.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
- 7.5.1. Uterine Sarcoma
- 7.5.2. Endometrial Carcinomas
7.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
- 7.6.1. Ultrasound Scanning
  - 7.6.1.1. Abdominal Ultrasound
  - 7.6.1.2. Transvaginal Ultrasound
- 7.6.2. Biopsy
  - 7.6.2.1. Endometrial Biopsy
  - 7.6.2.2. Hysteroscopy
  - 7.6.2.3. Dilation and curettage
- 7.6.3. Blood tests
  - 7.6.3.1. Complete blood Count
  - 7.6.3.2. CA-125 blood test
7.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
- 7.7.1. Ultrasound Scanning
  - 7.7.1.1. Abdominal Ultrasound
  - 7.7.1.2. Transvaginal Ultrasound
- 7.7.2. Biopsy
  - 7.7.2.1. Endometrial Biopsy
  - 7.7.2.2. Hysteroscopy
  - 7.7.2.3. Dilation and curettage
- 7.7.3. Blood tests
  - 7.7.3.1. Complete blood Count
  - 7.7.3.2. CA-125 blood test
7.8. Historical Market Size Analysis 2019 - 2024, By End User
- 7.8.1. Hospitals
- 7.8.2. Ambulatory Surgical Centers
- 7.8.3. Cancer Research Centers
- 7.8.4. Specialized Clinics
- 7.8.5. Diagnostic Laboratories
- 7.8.6. Others
7.9. Market Size Analysis 2025 - 2032, By End User
- 7.9.1. Hospitals
- 7.9.2. Ambulatory Surgical Centers
- 7.9.3. Cancer Research Centers
- 7.9.4. Specialized Clinics
- 7.9.5. Diagnostic Laboratories
- 7.9.6. Others
7.10. Drivers and Restraints: Impact Analysis
7.11. Market Attractiveness Analysis
- 7.11.1. By Cancer Type
- 7.11.2. By Test Type
- 7.11.3. By End user
- 7.11.4. By Country

8. Asia Pacific Excluding China Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

8.1. Introduction
8.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
- 8.2.1. China
- 8.2.2. India
- 8.2.3. Japan
- 8.2.4. Australia and New Zealand
- 8.2.5. Rest of APAC
8.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
- 8.3.1. China
- 8.3.2. India
- 8.3.3. Japan
- 8.3.4. Australia and New Zealand
- 8.3.5. Rest of APAC
8.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
- 8.4.1. Uterine Sarcoma
- 8.4.2. Endometrial Carcinomas
8.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
- 8.5.1. Uterine Sarcoma
- 8.5.2. Endometrial Carcinomas
8.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
- 8.6.1. Ultrasound Scanning
  - 8.6.1.1. Abdominal Ultrasound
  - 8.6.1.2. Transvaginal Ultrasound
- 8.6.2. Biopsy
  - 8.6.2.1. Endometrial Biopsy
  - 8.6.2.2. Hysteroscopy
  - 8.6.2.3. Dilation and curettage
- 8.6.3. Blood tests
  - 8.6.3.1. Complete blood Count
  - 8.6.3.2. CA-125 blood test
8.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
- 8.7.1. Ultrasound Scanning
  - 8.7.1.1. Abdominal Ultrasound
  - 8.7.1.2. Transvaginal Ultrasound
- 8.7.2. Biopsy
  - 8.7.2.1. Endometrial Biopsy
  - 8.7.2.2. Hysteroscopy
  - 8.7.2.3. Dilation and curettage
- 8.7.3. Blood tests
  - 8.7.3.1. Complete blood Count
  - 8.7.3.2. CA-125 blood test
8.8. Historical Market Size Analysis 2019 - 2024, By End User
- 8.8.1. Hospitals
- 8.8.2. Ambulatory Surgical Centers
- 8.8.3. Cancer Research Centers
- 8.8.4. Specialized Clinics
- 8.8.5. Diagnostic Laboratories
- 8.8.6. Others
8.9. Market Size Analysis 2025 - 2032, By End User
- 8.9.1. Hospitals
- 8.9.2. Ambulatory Surgical Centers
- 8.9.3. Cancer Research Centers
- 8.9.4. Specialized Clinics
- 8.9.5. Diagnostic Laboratories
- 8.9.6. Others
8.10. Drivers and Restraints: Impact Analysis
8.11. Market Attractiveness Analysis
- 8.11.1. By Cancer Type
- 8.11.2. By Test Type
- 8.11.3. By End user
- 8.11.4. By Country

9. China Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

9.1. Introduction
9.2. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
- 9.2.1. Uterine Sarcoma
- 9.2.2. Endometrial Carcinomas
9.3. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
- 9.3.1. Uterine Sarcoma
- 9.3.2. Endometrial Carcinomas
9.4. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
- 9.4.1. Ultrasound Scanning
  - 9.4.1.1. Abdominal Ultrasound
  - 9.4.1.2. Transvaginal Ultrasound
- 9.4.2. Biopsy
  - 9.4.2.1. Endometrial Biopsy
  - 9.4.2.2. Hysteroscopy
  - 9.4.2.3. Dilation and curettage
- 9.4.3. Blood tests
  - 9.4.3.1. Complete blood Count
  - 9.4.3.2. CA-125 blood test
9.5. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
- 9.5.1. Ultrasound Scanning
  - 9.5.1.1. Abdominal Ultrasound
  - 9.5.1.2. Transvaginal Ultrasound
- 9.5.2. Biopsy
  - 9.5.2.1. Endometrial Biopsy
  - 9.5.2.2. Hysteroscopy
  - 9.5.2.3. Dilation and curettage
- 9.5.3. Blood tests
  - 9.5.3.1. Complete blood Count
  - 9.5.3.2. CA-125 blood test
9.6. Historical Market Size Analysis 2019 - 2024, By End User
- 9.6.1. Hospitals
- 9.6.2. Ambulatory Surgical Centers
- 9.6.3. Cancer Research Centers
- 9.6.4. Specialized Clinics
- 9.6.5. Diagnostic Laboratories
- 9.6.6. Others
9.7. Market Size Analysis 2025 - 2032, By End User
- 9.7.1. Hospitals
- 9.7.2. Ambulatory Surgical Centers
- 9.7.3. Cancer Research Centers
- 9.7.4. Specialized Clinics
- 9.7.5. Diagnostic Laboratories
- 9.7.6. Others
9.8. Drivers and Restraints: Impact Analysis
9.9. Market Attractiveness Analysis
- 9.9.1. By Cancer Type
- 9.9.2. By Test Type
- 9.9.3. By End user
- 9.9.4. By Country

10. Middle East and Africa (MEA) Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

10.1. Introduction
10.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
- 10.2.1. South Africa
- 10.2.2. Saudi Arabia
- 10.2.3. Rest of MEA
10.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
- 10.3.1. South Africa
- 10.3.2. Saudi Arabia
- 10.3.3. Rest of MEA
10.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
- 10.4.1. Uterine Sarcoma
- 10.4.2. Endometrial Carcinomas
10.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
- 10.5.1. Uterine Sarcoma
- 10.5.2. Endometrial Carcinomas
10.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
- 10.6.1. Ultrasound Scanning
  - 10.6.1.1. Abdominal Ultrasound
  - 10.6.1.2. Transvaginal Ultrasound
- 10.6.2. Biopsy
  - 10.6.2.1. Endometrial Biopsy
  - 10.6.2.2. Hysteroscopy
  - 10.6.2.3. Dilation and curettage
- 10.6.3. Blood tests
  - 10.6.3.1. Complete blood Count
  - 10.6.3.2. CA-125 blood test
10.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
- 10.7.1. Ultrasound Scanning
  - 10.7.1.1. Abdominal Ultrasound
  - 10.7.1.2. Transvaginal Ultrasound
- 10.7.2. Biopsy
  - 10.7.2.1. Endometrial Biopsy
  - 10.7.2.2. Hysteroscopy
  - 10.7.2.3. Dilation and curettage
- 10.7.3. Blood tests
  - 10.7.3.1. Complete blood Count
  - 10.7.3.2. CA-125 blood test
10.8. Historical Market Size Analysis 2019 - 2024, By End User
- 10.8.1. Hospitals
- 10.8.2. Ambulatory Surgical Centers
- 10.8.3. Cancer Research Centers
- 10.8.4. Specialized Clinics
- 10.8.5. Diagnostic Laboratories
- 10.8.6. Others
10.9. Market Size Analysis 2025 - 2032, By End User
- 10.9.1. Hospitals
- 10.9.2. Ambulatory Surgical Centers
- 10.9.3. Cancer Research Centers
- 10.9.4. Specialized Clinics
- 10.9.5. Diagnostic Laboratories
- 10.9.6. Others
10.10. Drivers and Restraints: Impact Analysis
10.11. Market Attractiveness Analysis
- 10.11.1. By Cancer Type
- 10.11.2. By Test Type
- 10.11.3. By End user
- 10.11.4. By Country

11. Forecast Factors: Relevance and Impact

12. Competition Landscape

12.1. Competition Dashboard
12.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3. Key Players
- 12.3.1. Abbott
- 12.3.2. Roche Holdings AG
- 12.3.3. Siemens AG
- 12.3.4. Danaher
- 12.3.5. BioMerieux SA

13. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Region

13.1. Introduction
- 13.1.1. Basis Point Share (BPS) Analysis by Region
- 13.1.2. Y-o-Y Growth Projections by Region
13.2. Historical Market Size Analysis 2019 - 2024, By Region
- 13.2.1. North America
- 13.2.2. Latin America
- 13.2.3. Europe
- 13.2.4. Asia Pacific Excluding China
- 13.2.5. China
- 13.2.6. Middle East and Africa (MEA)
13.3. Market Size Analysis 2025 - 2032, By Region
- 13.3.1. North America
- 13.3.2. Latin America
- 13.3.3. Europe
- 13.3.4. Asia Pacific Excluding China
- 13.3.5. China
- 13.3.6. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis by Region

14. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Cancer Type

14.1. Introduction
- 14.1.1. Basis Point Share (BPS) Analysis by Product Type
- 14.1.2. Y-o-Y Growth Projections by Product Type
14.2. Historical Market Size Analysis 2019 - 2024, By Cancer Type
- 14.2.1. Uterine Sarcoma
- 14.2.2. Endometrial Carcinomas
14.3. Market Size Analysis 2025 - 2032, By Cancer Type
- 14.3.1. Uterine Sarcoma
- 14.3.2. Endometrial Carcinomas
14.4. Market Attractiveness Analysis by Cancer Type

15. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Diagnostic Test Type

15.1. Introduction
- 15.1.1. Basis Point Share (BPS) Analysis by Test Type
- 15.1.2. Y-o-Y Growth Projections by Test Type
15.2. Historical Market Size Analysis 2019 - 2024, By Test Type
- 15.2.1. Ultrasound Scanning
  - 15.2.1.1. Abdominal Ultrasound
  - 15.2.1.2. Transvaginal Ultrasound
- 15.2.2. Biopsy
  - 15.2.2.1. Endometrial Biopsy
  - 15.2.2.2. Hysteroscopy
  - 15.2.2.3. Dilation and curettage
- 15.2.3. Blood tests
  - 15.2.3.1. Complete blood Count
  - 15.2.3.2. CA-125 blood test
15.3. Market Size Analysis 2025 - 2032, By Test Type
- 15.3.1. Ultrasound Scanning
  - 15.3.1.1. Abdominal Ultrasound
  - 15.3.1.2. Transvaginal Ultrasound
- 15.3.2. Biopsy
  - 15.3.2.1. Endometrial Biopsy
  - 15.3.2.2. Hysteroscopy
  - 15.3.2.3. Dilation and curettage
- 15.3.3. Blood tests
  - 15.3.3.1. Complete blood Count
  - 15.3.3.2. CA-125 blood test
15.4. Market Attractiveness Analysis by Test Type

16. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By End User

16.1. Introduction
- 16.1.1. Basis Point Share (BPS) Analysis by End User
- 16.1.2. Y-o-Y Growth Projections by End User
16.2. Historical Market Size Analysis 2019 - 2024, By End User
- 16.2.1. Hospitals
- 16.2.2. Ambulatory Surgical Centers
- 16.2.3. Cancer Research Centers
- 16.2.4. Specialized Clinics
- 16.2.5. Diagnostic Laboratories
- 16.2.6. Others
16.3. Market Size Analysis 2025 - 2032, By End User
- 16.3.1. Hospitals
- 16.3.2. Ambulatory Surgical Centers
- 16.3.3. Cancer Research Centers
- 16.3.4. Specialized Clinics
- 16.3.5. Diagnostic Laboratories
- 16.3.6. Others
16.4. Market Attractiveness Analysis by End User

17. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

17.1. Market Size and Y-o-Y Growth
17.2. Absolute $ Opportunity

18. Assumptions and Acronyms Used

A glossary of assumption and acronyms used in the report

Uterine Cancer Diagnostic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032